Ionis Pharmaceuticals' experimental drug, donidalorsen, administered through subcutaneous injection, showed a significant reduction in the rate of painful attacks for patients with hereditary angioedema. The patients received an 80 milligram dose of the drug every four or eight weeks.from Science News - Times of India https://ift.tt/ZTrOXnE
via
Comments
Post a Comment